• Consensus Rating: Hold
  • Consensus Price Target: $52.46
  • Forecasted Upside: -6.82%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 9 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$56.30
▼ -0.62 (-1.09%)

This chart shows the closing price for CTLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catalent Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTLT

Analyst Price Target is $52.46
▼ -6.82% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Catalent in the last 3 months. The average price target is $52.46, with a high forecast of $63.50 and a low forecast of $42.00. The average price target represents a -6.82% upside from the last price of $56.30.

This chart shows the closing price for CTLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in Catalent. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
10/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
1/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
4/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
7/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
10/15/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
1/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
4/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$63.50Low
2/20/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$63.50Low
2/6/2024StephensReiterated RatingOverweight ➝ Equal Weight$63.50Low
2/6/2024UBS GroupReiterated RatingBuy ➝ Neutral$58.00 ➝ $63.50Low
2/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$58.00 ➝ $63.50Low
1/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $47.00Low
11/16/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$58.00 ➝ $55.00Low
11/16/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$50.00 ➝ $42.00Low
11/16/2023Robert W. BairdUpgradeNeutral ➝ Outperform$45.00 ➝ $53.00Low
11/14/2023William BlairReiterated RatingMarket PerformLow
10/31/2023William BlairReiterated RatingMarket PerformLow
9/29/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$55.00 ➝ $50.00Low
9/5/2023ArgusUpgradeHold ➝ Buy$62.00Low
9/1/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$42.00 ➝ $55.00Low
8/31/2023Bank of AmericaBoost TargetUnderperform ➝ Underperform$39.00 ➝ $46.00Low
8/30/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$52.00 ➝ $55.00Low
8/30/2023William BlairReiterated RatingMarket PerformLow
8/30/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$51.00 ➝ $58.00Low
8/30/2023UBS GroupBoost TargetBuy ➝ Buy$55.00 ➝ $58.00Low
8/15/2023Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$37.00 ➝ $45.00Low
7/20/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$43.00N/A
6/30/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$49.00Low
6/14/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$45.00 ➝ $44.00Low
6/13/2023UBS GroupLower Target$60.00 ➝ $55.00Low
6/13/2023Bank of AmericaBoost Target$28.00 ➝ $33.00Low
6/13/2023Robert W. BairdBoost Target$35.00 ➝ $47.00Low
6/12/2023BarclaysBoost Target$35.00 ➝ $42.00Low
5/22/2023Morgan StanleyLower Target$85.00 ➝ $50.00Low
5/22/2023Deutsche Bank AktiengesellschaftBoost Target$29.00 ➝ $37.00Low
5/22/2023Robert W. BairdLower Target$53.00 ➝ $35.00Low
5/21/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$90.00 ➝ $45.00Low
5/21/2023BarclaysLower Target$40.00 ➝ $35.00Low
5/15/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$55.00 ➝ $29.00Low
5/9/2023Deutsche Bank AktiengesellschaftLower Target$72.00 ➝ $55.00Low
5/8/2023Royal Bank of CanadaLower Target$58.00 ➝ $41.00Low
5/8/2023Bank of AmericaDowngradeNeutral ➝ Underperform$28.00Low
4/25/2023Bank of AmericaLower Target$78.00 ➝ $49.00Low
4/17/2023BarclaysLower Target$70.00 ➝ $40.00Low
4/17/2023Deutsche Bank AktiengesellschaftLower Target$88.00 ➝ $72.00Low
4/17/2023Robert W. BairdDowngradeOutperform ➝ Neutral$82.00 ➝ $53.00Low
4/14/2023William BlairDowngradeOutperform ➝ Market PerformLow
4/10/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$79.00 ➝ $88.00Low
4/3/2023BarclaysDowngradeOverweight ➝ Equal Weight$82.00 ➝ $70.00Low
2/9/2023Deutsche Bank AktiengesellschaftBoost TargetHold$65.00 ➝ $79.00Low
2/9/2023Morgan StanleyBoost TargetOverweight$81.00 ➝ $85.00Low
2/8/2023Royal Bank of CanadaBoost Target$73.00 ➝ $85.00Low
2/8/2023Bank of AmericaBoost Target$60.00 ➝ $78.00Low
2/8/2023Robert W. BairdBoost TargetOutperform$75.00 ➝ $82.00Low
2/8/2023BarclaysBoost TargetOverweight$58.00 ➝ $82.00Low
1/24/2023BarclaysLower TargetOverweight$62.00 ➝ $58.00Low
11/7/2022ArgusDowngradeBuy ➝ HoldLow
11/3/2022Morgan StanleyLower TargetOverweight$120.00 ➝ $81.00Low
11/2/2022Royal Bank of CanadaLower TargetOutperform$125.00 ➝ $73.00Low
11/2/2022BarclaysLower TargetOverweight$105.00 ➝ $62.00Low
11/2/2022Robert W. BairdLower Target$123.00 ➝ $75.00N/A
11/2/2022KeyCorpLower TargetOverweight$125.00 ➝ $85.00Low
11/2/2022Bank of AmericaDowngradeBuy ➝ Neutral$125.00 ➝ $60.00Low
10/6/2022BarclaysLower TargetOverweight$115.00 ➝ $105.00Low
9/6/2022StephensLower Target$145.00Low
8/30/2022Jefferies Financial GroupLower TargetBuy$130.00 ➝ $110.00Low
8/30/2022UBS GroupLower Target$145.00 ➝ $132.00Low
8/30/2022Morgan StanleyLower TargetOverweight$132.00 ➝ $120.00Low
8/30/2022Deutsche Bank AktiengesellschaftLower TargetHold$110.00 ➝ $105.00Low
8/30/2022Royal Bank of CanadaLower TargetOutperform$155.00 ➝ $125.00Low
8/30/2022Bank of AmericaLower TargetBuy$140.00 ➝ $125.00Low
8/30/2022BarclaysLower TargetOverweight$130.00 ➝ $115.00Low
4/12/2022Deutsche Bank AktiengesellschaftLower TargetHold$129.00 ➝ $110.00High
2/2/2022Morgan StanleyLower TargetOverweight$160.00 ➝ $145.00Low
1/27/2022BarclaysLower TargetOverweight$160.00 ➝ $130.00Low
12/16/2021BarclaysInitiated CoverageOverweight$160.00Low
11/3/2021Morgan StanleyBoost TargetOverweight$147.00 ➝ $160.00Low
11/3/2021Royal Bank of CanadaBoost TargetOutperform$145.00 ➝ $155.00Low
9/8/2021Deutsche Bank AktiengesellschaftBoost TargetHold$123.00 ➝ $162.00Medium
8/31/2021UBS GroupBoost TargetBuy$138.00 ➝ $145.00Low
8/31/2021KeyCorpBoost TargetOverweight$142.00 ➝ $155.00Low
8/31/2021Bank of AmericaBoost TargetBuy$140.00 ➝ $160.00Low
8/31/2021Morgan StanleyBoost TargetOverweight$135.00 ➝ $147.00Low
8/31/2021Royal Bank of CanadaBoost TargetOutperform$137.00 ➝ $145.00Low
3/2/2021ArgusBoost TargetBuy$130.00 ➝ $140.00Medium
2/3/2021Morgan StanleyBoost TargetOverweight$115.00 ➝ $135.00High
2/3/2021UBS GroupBoost TargetBuy$115.00 ➝ $135.00High
2/3/2021Royal Bank of CanadaBoost TargetOutperform$125.00 ➝ $137.00High
1/8/2021JPMorgan Chase & Co.Boost TargetOverweight$110.00 ➝ $130.00Low
11/5/2020Deutsche Bank AktiengesellschaftBoost TargetHold$91.00 ➝ $100.00Low
11/4/2020Robert W. BairdBoost TargetOutperform$100.00 ➝ $109.00High
11/4/2020Jefferies Financial GroupBoost TargetBuy$107.00 ➝ $115.00High
11/4/2020UBS GroupBoost TargetBuy$105.00 ➝ $115.00High
11/4/2020Royal Bank of CanadaBoost TargetOutperform$98.00 ➝ $105.00High
11/4/2020Morgan StanleyBoost TargetOverweight$98.00 ➝ $115.00High
9/24/2020ArgusBoost Target$100.00 ➝ $110.00Low
9/4/2020Deutsche Bank AktiengesellschaftBoost TargetIn-Line ➝ Hold$62.00 ➝ $91.00Low
9/1/2020Royal Bank of CanadaBoost Target$94.00 ➝ $98.00Low
9/1/2020Morgan StanleyBoost TargetOverweight$95.00 ➝ $98.00High
9/1/2020Robert W. BairdBoost TargetPositive ➝ Outperform$90.00 ➝ $100.00High
8/11/2020Jefferies Financial GroupReiterated RatingBuy$105.00High
7/31/2020Morgan StanleyBoost TargetOverweight$75.00 ➝ $95.00Low
7/21/2020UBS GroupBoost TargetBuy$77.00 ➝ $97.00Low
7/14/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$78.00 ➝ $86.00Medium
6/26/2020Robert W. BairdBoost TargetOutperform$74.00 ➝ $80.00Medium
6/25/2020ArgusInitiated CoverageBuyMedium
5/6/2020Robert W. BairdBoost TargetOutperform$63.00 ➝ $74.00Low
5/6/2020Morgan StanleyBoost TargetOverweight$57.00 ➝ $75.00Low
5/6/2020UBS GroupBoost TargetBuy$70.00 ➝ $77.00Low
5/6/2020Deutsche Bank AktiengesellschaftBoost TargetHold$59.00 ➝ $62.00High
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$65.00High
4/13/2020Robert W. BairdLower TargetOutperform$67.00 ➝ $63.00Low
3/27/2020Morgan StanleyLower TargetOverweight$67.00 ➝ $57.00High
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$59.00High
2/4/2020Robert W. BairdReiterated RatingOutperform$60.00 ➝ $67.00High
2/4/2020Morgan StanleyBoost TargetOverweight$64.00 ➝ $67.00Medium
1/27/2020StephensBoost TargetOverweight$65.00 ➝ $75.00Low
10/17/2019StephensInitiated CoverageOverweight$56.00High
8/28/2019Robert W. BairdBoost TargetOutperform$50.00 ➝ $60.00Low
8/28/2019Morgan StanleyBoost TargetOverweight$50.00 ➝ $61.00Low
7/23/2019UBS GroupBoost TargetBuy$64.00Low
6/21/2019Jefferies Financial GroupUpgradeHold ➝ Buy$50.00 ➝ $62.00High
4/16/2019Morgan StanleyBoost TargetOverweight$46.00 ➝ $50.00High
4/16/2019Jefferies Financial GroupBoost TargetHold$44.00 ➝ $50.00High
4/16/2019UBS GroupUpgradeNeutral ➝ Buy$43.00 ➝ $54.00High
(Data available from 4/12/2019 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 21 very positive mentions
  • 32 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
9/15/2023
  • 16 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/15/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/14/2023
  • 11 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/14/2023
  • 15 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/13/2024
  • 20 very positive mentions
  • 26 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
2/12/2024
  • 15 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/13/2024
  • 17 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/12/2024

Current Sentiment

  • 17 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Catalent logo
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Read More

Today's Range

Now: $56.30
Low: $56.20
High: $57.04

50 Day Range

MA: $56.99
Low: $55.79
High: $59.82

52 Week Range

Now: $56.30
Low: $31.45
High: $64.46

Volume

1,956,712 shs

Average Volume

2,656,208 shs

Market Capitalization

$10.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalent?

The following Wall Street analysts have issued reports on Catalent in the last year: Argus, Bank of America Co., Barclays PLC, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stephens, StockNews.com, TheStreet, UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for CTLT.

What is the current price target for Catalent?

12 Wall Street analysts have set twelve-month price targets for Catalent in the last year. Their average twelve-month price target is $52.46, suggesting a possible downside of 7.0%. UBS Group AG has the highest price target set, predicting CTLT will reach $63.50 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $42.00 for Catalent in the next year.
View the latest price targets for CTLT.

What is the current consensus analyst rating for Catalent?

Catalent currently has 1 sell rating, 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CTLT, but not buy more shares or sell existing shares.
View the latest ratings for CTLT.

What other companies compete with Catalent?

How do I contact Catalent's investor relations team?

Catalent's physical mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company's listed phone number is (732) 537-6200 and its investor relations email address is [email protected]. The official website for Catalent is www.catalent.com. Learn More about contacing Catalent investor relations.